A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome
NCT00251511
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
60
Enrollment
OTHER
Sponsor class
Stopped
Sponsor terminated trial
Conditions
Myelodysplastic Syndrome
Interventions
DRUG:
Arsenic Trioxide
Sponsor
Veeda Oncology
Collaborators
[object Object]